Provectus Biopharmaceuticals, Inc. Share Price
Equities
PVCT
US74373P1084
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.195 USD | -1.74% | +0.15% | +103.23% |
Sales 2022 | 0.99 82.53 | Sales 2023 | 0.56 46.54 | Capitalization | 40.27M 3.36B |
---|---|---|---|---|---|
Net income 2022 | -3M -250M | Net income 2023 | -3M -250M | EV / Sales 2022 | 4,81,21,944 x |
Net Debt 2022 | 2.16M 180M | Net Debt 2023 | 2.95M 246M | EV / Sales 2023 | 7,75,02,175 x |
P/E ratio 2022 |
-12.8
x | P/E ratio 2023 |
-13
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.58% |
1 day | -1.74% | ||
1 week | +0.15% | ||
Current month | +6.67% | ||
1 month | +2.63% | ||
3 months | +72.81% | ||
6 months | +155.37% | ||
Current year | +103.23% |
Managers | Title | Age | Since |
---|---|---|---|
Edward Pershing
CEO | Chief Executive Officer | 71 | 27/18/27 |
Eric A. Wachter
FOU | Founder | 61 | 01/02/01 |
Heather Raines
DFI | Director of Finance/CFO | 58 | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric A. Wachter
FOU | Founder | 61 | 01/02/01 |
John W. Lacey
BRD | Director/Board Member | 76 | 27/18/27 |
President | 55 | 03/17/03 |
Date | Price | Change | Volume |
---|---|---|---|
30/24/30 | 0.195 | -1.74% | 27 570 |
26/24/26 | 0.1985 | +1.07% | 39,686 |
25/24/25 | 0.1964 | +1.24% | 251,000 |
24/24/24 | 0.194 | -0.41% | 67,734 |
23/24/23 | 0.1948 | 0.00% | 138,051 |
Delayed Quote OTC Markets, April 30, 2024 at 12:56 am IST
More quotes1st Jan change | Capi. | |
---|---|---|
+103.23% | 83.28M | |
-2.88% | 103B | |
+1.41% | 95.28B | |
+1.46% | 22.15B | |
-16.48% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.10% | 16.05B | |
+5.49% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- PVCT Stock